Literature DB >> 27799972

Species-specific PCR for the Diagnosis and Determination of Antibiotic Susceptibilities of Brucella Strains Isolated from Tehran, Iran.

Gholam Reza Irajian1, Faramarz Masjedian Jazi1, Reza Mirnejad2, Vahhab Piranfar2, Taghi Zahraei Salehi3, Noor Amir Mozafari1, Ehsanollah Ghaznavi-Rad4, Mahmoud Khormali3.   

Abstract

BACKGROUND: Brucellosis is an endemic zoonotic disease in the Middle East. This study intended to design a uniplex PCR assay for the detection and differentiation of Brucella at the species level and determining the antibiotic susceptibility pattern of Brucella in Iran.
METHODS: Sixty-eight Brucella specimens (38 animal and 30 human specimens) were analyzed using PCR (using one pair of primers). Antibiotic susceptibility patterns were evaluated and compared using the E-Test and disk diffusion susceptibility test. Tigecycline susceptibility pattern was compared with other antibiotics.
RESULTS: Thirty six isolates of B. melitensis, 2 isolates of B. abortus and 1 isolate of B. suis from the 38 animal specimens, 24 isolates of B. melitensis and 6 isolates of B. abortus from the 30 human specimens were differentiated. The MIC50 values of doxycycline for human and animal specimens were 125 and 10 μg/ml, respectively, tigecycline 0.064 μg/ml for human specimens and 0.125μg/ml for animal specimens, and trimethoprim/ sulfamethoxazole and ciprofloxacin 0.065 and 0.125μg/ml, respectively, for both human and animal specimens. The highest MIC50 value of streptomycin in the human specimens was 0.5μg/ml and 1μg/ml for the animal specimens. The greatest resistance shown was to tetracycline and gentamicin, respectively.
CONCLUSION: Uniplex PCR for the detection and differentiation of Brucella at the strain level is faster and less expensive than multiplex PCR, and the antibiotics doxycycline, rifampin, trimethoprim-sulfamethoxazole, ciprofloxacin, and ofloxacin are the most effective antibiotics for treating brucellosis. Resistance to tigecycline is increasing, and we recommend that it be used in a combination regimen.

Entities:  

Keywords:  Antibiotic Susceptibilities; Brucella; Tigecycline; Uniplex PCR

Year:  2016        PMID: 27799972      PMCID: PMC5079456     

Source DB:  PubMed          Journal:  Iran J Pathol        ISSN: 1735-5303


  33 in total

1.  Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis.

Authors:  Mohammad Reza Hasanjani Roushan; Mino Mohraz; Nasser Janmohammadi; Mahmood Hajiahmadi
Journal:  Pediatr Infect Dis J       Date:  2006-06       Impact factor: 2.129

2.  In vitro activities of six new fluoroquinolones against Brucella melitensis.

Authors:  I Trujillano-Martín; E García-Sánchez; I M Martínez; M J Fresnadillo; J E García-Sánchez; J A García-Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Laboratory techniques in brucellosis.

Authors:  G G Alton; L M Jones; D E Pietz
Journal:  Monogr Ser World Health Organ       Date:  1975

4.  Pathogenicity and immunogenicity of streptomycin-dependent mutants of Brucella.

Authors:  E M SIMON; D T BERMAN
Journal:  J Bacteriol       Date:  1962-06       Impact factor: 3.490

5.  In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.

Authors:  S Kilic; M Dizbay; H Cabadak
Journal:  J Chemother       Date:  2008-02       Impact factor: 1.714

6.  Antimicrobial susceptibilities of Brucella isolates from various clinical specimens.

Authors:  Yasemin Bayram; Hanifi Korkoca; Cenk Aypak; Mehmet Parlak; Aytekin Cikman; Selcuk Kilic; Mustafa Berktas
Journal:  Int J Med Sci       Date:  2011-03-03       Impact factor: 3.738

7.  Reemergence of human and animal brucellosis, bulgaria.

Authors:  Gianluca Russo; Paolo Pasquali; Roumiana Nenova; Tsviatko Alexandrov; Stanislav Ralchev; Vincenzo Vullo; Giovanni Rezza; Todor Kantardjiev
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

8.  Zoonoses: a potential obstacle to the growing wildlife industry of Namibia.

Authors:  Kudakwashe Magwedere; Maria Y Hemberger; Louw C Hoffman; Francis Dziva
Journal:  Infect Ecol Epidemiol       Date:  2012-10-15

9.  The Antibacterial Activity of Selected Labiatae (Lamiaceae) Essential Oils against Brucella melitensis.

Authors:  Ayman Al-Mariri; Mazen Safi
Journal:  Iran J Med Sci       Date:  2013-03

10.  Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.

Authors:  Javier Ariza; Mile Bosilkovski; Antonio Cascio; Juan D Colmenero; Michael J Corbel; Matthew E Falagas; Ziad A Memish; Mohammad Reza Hasanjani Roushan; Ethan Rubinstein; Nikolaos V Sipsas; Javier Solera; Edward J Young; Georgios Pappas
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more
  4 in total

Review 1.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

2.  In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China.

Authors:  Zhi-Guo Liu; Dong-Dong Di; Miao Wang; Ri-Hong Liu; Hong-Yan Zhao; Dong-Ri Piao; Zhong-Zhi Zhao; Yong-Qing Hao; Ya-Nan Du; Hai Jiang; Bu-Yun Cui; Xian-Zhu Xia
Journal:  BMC Infect Dis       Date:  2018-01-16       Impact factor: 3.090

3.  Antimicrobial susceptibility of Brucella spp. isolated from Iranian patients during 2016 to 2018.

Authors:  Saeed Alamian; Maryam Dadar; Afshar Etemadi; Davoud Afshar; Mohammad Mehdi Alamian
Journal:  Iran J Microbiol       Date:  2019-10

4.  Persister cells formation and expression of type II Toxin-Antitoxin system genes in Brucella melitensis (16M) and Brucella abortus (B19).

Authors:  Fatemeh Amraei; Negar Narimisa; Behrooz Sadeghi Kalani; Vahid Lohrasbi; Faramarz Masjedian Jazi
Journal:  Iran J Pathol       Date:  2020-02-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.